ArticleInflammation2025
A Comparative Analysis Dissecting the Immune Landscape of Vitiligo and Melanoma from a single-cell Perspective: Two Sides of the Same Coin?
Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Minimally invasive 1 mm skin biopsies capture site-specific transcriptomic heterogeneity in vitiligo.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundVitiligo and melanoma, while sharing overlapping immune responses and cellular environments, represent distinct dermatological conditions. A comprehensive comparison of the immune microenvironments in vitiligo and melanoma through detailed single-cell analysis has not yet been thoroughly defined.
methodsIntegrated single-cell RNA sequencing (scRNA-seq) data were obtained from healthy controls, vitiligo and melanoma patients. Comprehensive analyses including differential gene expression, enrichment analysis, regulatory network, pseudotime trajectory and cell-cell interaction were conducted to elucidate the roles of various cell subtypes and their interactions within the disease microenvironments.
resultsIn vitiligo, melanocytes undergo stress-induced activation of multiple cell death pathways and immune activation, whereas in melanoma, they survive by suppressing death signals. The immune microenvironment of vitiligo is dominated by CD8 + T cells, characterized by IFN-γ-CXCL9/10-CXCR3 axis-mediated melanocyte elimination. Stressed fibroblasts and stressed keratinocytes amplify these pro-inflammatory signals. In contrast, the melanoma microenvironment is regulated by Tregs and cancer-associated fibroblasts, leading to impaired cytotoxic function of CD8 + T cells.
conclusionsThe divergent immune microenvironments of vitiligo and melanoma are characterized by immune activation versus immune evasion. These findings provide novel insights into potential therapeutic targets for both conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.